PEGylated Recombinant Human Interferon and Nomenclature

doi:10.13523/j.cb.20140615

China Biotechnology

2014, Vol. 34

Issue (06): 105-109 DOI: 10.13523/j.cb.20140615

PEGylated Recombinant Human Interferon and Nomenclature

REN Yue-ming

Chinese Pharmacopeia Commission, Beijing 100061, China

Download:

HTML

PDF(415KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

A lot of PEGylated proteins have been approved. Therefore, the naming scheme of Chinese Approved Drug Name relating to this kind of products must be revised to adapting their development.The progress of PEGylation technology and INN for these drugs were introduced. The nomenclature for PEGylated recombinant protein in China was discussed.

Key words： PEGylation Recombinant human interferon Nomenclature

Received: 17 April 2014 Published: 25 June 2014

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

REN Yue-ming. PEGylated Recombinant Human Interferon and Nomenclature. China Biotechnology, 2014, 34(06): 105-109.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20140615 OR https://manu60.magtech.com.cn/biotech/Y2014/V34/I06/105

[1] Kang J S, Deluca P P, Lee K C. Emerging PEGylated drugs. Expert Opin Emerg Drugs,2009,14(2):363-380.

[2] Bailon P I, Won C Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv, 2009,6(1):1-16.

[3] Francesco M Veronese, Anna Mero. The impact of PEGylation on biological therapies. Biodrugs, 2008, 22 (5): 315-329.

[4] Robert W Payne, Brian M Murphy, Mark Cornell. Product development issues for PEGylated proteins. Pharmaceutical Development and Technology, 2011, 16(5): 423-440.

[5] Fee C J, Van Alstine J A. PEG-proteins: Reaction engineering and separation issues. Chem Engineer Sci, 2006,61:924-939.

[6] Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv, 2006,13:399-409.

[7] Fee C J. Size comparison between proteins PEGylated with branched and linear Poly(ethylene glycol) molecules. Biotechnol Biotechnol Bioengineer, 2007,98:725-731.

[8] WHO. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances Executive Summary.09/2013. http://www.who.int/medicines/services/inn/56th_Executive_Summary.pdf?ua=1.

[9] 任跃明. 国际非专利药品名(INN)在我国生物制品命名领域的应用.中国药品标准, 2008,9(3):189-194. Ren Y M. Prospect of International Nonproprietary Name in Chinese Biologicals.Drug Standard of China,2008,9(3):189-194.

[10] 《中国药典》. 2010年版. 三部.附录5. Pharmacopoeia of the People's Republic of China. 2010 Edition. Vol Ⅲ. Appendix 5.

[1]	GUO Zhong-ping, XU Li. Revision of the General Policies of Nomenclature for Biological Products in China[J]. China Biotechnology, 2017, 37(8): 110-118.

[2]	Sheng-nan CHI,Zeng-lan LI,Chun ZHANG,Shuang YIN,Cui FENG,Qi WANG,Yong-dong LIU,Zhi-guo SU. Comparison of the Biological Activity of mPEG20k Modified and Transferrin Coupled Ciliary Neurotrophic Factor[J]. China Biotechnology, 2017, 37(12): 59-66.

[3]	TIAN Shuo, XU Chen, TAO Wen-Bing. The Advance in Long Effect Interferon Reserch[J]. China Biotechnology, 2010, 30(05): 122-127.

[4]	LIU A-Na, ZHOU Min-Yi, SONG Wen-Jin, LIU Jian-Beng. Determination of Content of Recombinant Human Interferon α1b Dry Powder Inhalation by HPLC[J]. China Biotechnology, 2010, 30(05): 92-95.

[5]	HUANG Xiang-Lu, DAO Sha-Sha, XU Chen, LI Ji, ZHOU Jian-Beng. Construction,Expression,Purification and Site-specific PEGylation of Integrated Interferon Mutant Cys72[J]. China Biotechnology, 2010, 30(04): 44-48.

[6]	WANG Xu-Dong, LI Xiao-Hui, SU Zhi-Guo, XIU Zhi-Long. Site-specific PEGylation Strategies and Suitable Modified Sites of Protein Drugs[J]. China Biotechnology, 2010, 30(04): 101-109.

Viewed

Full text

Abstract

Cited

Shared

Discussed